Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Varsha Gandhi, PhD, on Ibrutinib

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Advertisement

Advertisement




Oct
10
Today In Oncology
HER2-Positive Breast Cancer FDA Approves Triplet for Maintenance Therapy
FDA Approves Belzutifan in Combination With Lenvatinib for Advanced ccRCC
FDA Approves Atezolizumab in Combination With Chemotherapy for Stage III dMMR Colon Cancer
Cancer Statistics 2026: Incidence, Mortality, Survival, and Disparities in U.S. Oncology
FDA Approves First-Line Pirtobrutinib for CLL-SLL
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo